8-K: Vaxart's BARDA Project Scope Narrowed, Funding Continues

Vaxart announced BARDA's decision to definitively exclude certain work from its Project Agreement, while funding continues for ongoing Phase 2b COVID-19 trial participant follow-up.

Summary

• Vaxart received a follow-up notice on October 8, 2025, from ATI, clarifying the scope of its Project Agreement with BARDA.
• BARDA intends to conclusively delimit the Project Agreement to exclude previously paused work (Project Agreement No. 01; RRPV-24-04-NGVx-003).
• Approximately 5,000 participants already enrolled in the Phase 2b comparative study for Vaxart's oral pill COVID-19 vaccine candidate will continue to be followed.
• Vaxart will continue to receive funding for the evaluation of these enrolled participants.
• The company believes the trial data from these participants will provide useful insights and a strong foundation for its COVID program.

Sentiment

Score: 4

Explanation: While some funding continues for participant follow-up, the definitive exclusion of a significant portion of the BARDA-funded project is a negative development, reducing the overall scope and potential future funding from this source.

Positives

• Continued funding for the evaluation of approximately 5,000 enrolled participants in the Phase 2b COVID-19 vaccine trial.
• The company believes the data from these participants will provide useful insights and a strong foundation for its COVID program.

Negatives

• BARDA intends to conclusively exclude the previously paused work from the Project Agreement, indicating a significant reduction in the scope of the original government-funded project.
• The initial stop work order on August 5, 2025, followed by this definitive exclusion, signifies a negative development for the project's overall funding and scope.

Risks

• Risks and uncertainties associated with the company's ability to achieve successful results in the Phase 2b comparative study.
• The possibility that Trial outcomes may differ from current expectations of management.
• The company's continuing operating losses.

Future Outlook

Vaxart believes that the Trial data from the approximately 5,000 enrolled participants will provide useful insights and a strong foundation of evidence that could potentially advance its COVID program.

Management Comments

• We believe the Trial data from the enrolled participants will provide useful insights and a strong foundation of evidence that could potentially advance our COVID program.

Industry Context

The reduction in BARDA funding for a COVID-19 vaccine project reflects a broader trend of shifting priorities and reduced government funding for COVID-related initiatives as the pandemic evolves and other vaccine candidates advance. Companies reliant on such funding face increased pressure to demonstrate independent progress or secure alternative financing.

Stakeholder Impact

• Shareholders: Potential negative impact due to reduced project scope and government funding, offset slightly by continued funding for trial follow-up.
• Employees: Possible impact on personnel involved in the excluded 'Paused Work' components.
• BARDA/ATI: Their strategic priorities have shifted, leading to the delimitation of the project.

Next Steps

• Continue per protocol follow-up for the approximately 5,000 participants already enrolled in the Phase 2b comparative study.
• Evaluate the data from the enrolled participants to gain insights and potentially advance the COVID program.

Key Dates

Recommendation

The definitive exclusion of a significant portion of the BARDA-funded project is a clear negative, indicating a reduction in external support for a key program. However, the continuation of funding for the follow-up of 5,000 trial participants and the company's belief in the value of that data provide some mitigation. Investors should hold to assess the impact of the reduced project scope and await further trial results before making significant changes to their position.

Keywords

Vaxart, BARDA, COVID-19 vaccine, oral vaccine, Phase 2b trial, clinical trial, biotechnology, pharmaceuticals, government funding